secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001804220-22-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q3 revenues down 15% to $2.94B; ex-REGEN-COV up 11%; EPS $11.66
-------------------------------------------------------------------------

- GAAP diluted EPS $11.66 (Q3 2021: $14.33); non-GAAP $11.14 ($15.37).
- EYLEA U.S. net sales record $1.63B (+11% YoY); Dupixent global sales $2.33B (+40%).
- Aflibercept 8 mg met primary endpoints in DME and wet AMD pivotal trials; BLA submission planned late 2022.
- FDA granted EYLEA pediatric exclusivity through May 17, 2024; share repurchases $913M in Q3.
- Full-year 2022 GAAP R&D guidance raised to $3.515-$3.600B; SG&A to $2.010-$2.090B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/0001804220-22-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422022000029/regn-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001804220-22-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer